Thursday, April 7, 2016Contact: Sasha WalekMount Sinai Press Office(646) 605-5945[email protected]
Mount Sinai Researchers Identify Brain Insulin Resistance as Possible New Link Between Alzheimer’s Disease and Diabetes
Newswise — (NEW YORK – April 7, 2016) Several epidemiological studies support the hypothesis that diabetes increases a person’s risk for developing Alzheimer’s disease. However, new research from the Icahn School of Medicine at Mount Sinai published in the journal Alzheimer’s and Dementia suggests the reverse—that Alzheimer’s disease (AD) impairs insulin signaling in the portion of the brain responsible for regulating metabolism, making a person with AD more likely to develop diabetes. Findings also indicate that an increase of a particular group of amino acids in the blood could serve as a biomarker of impaired brain insulin signaling.
The study, conducted in mice, is part of ongoing research funded by the National Institutes of Health (NIH) to better understand the link between AD and diabetes. It is the first study to show that mice with AD have insulin resistance (a precursor to type II diabetes) in the hypothalamus, the area of the brain that regulates metabolism of nutrients such as fatty acids, glucose, and amino acids in tissues including muscle, liver, and fat. The mice with AD also showed elevated levels of branched chain amino acids (BCAA) in the blood. A previous study from the same team of researchers had demonstrated that brain insulin signaling regulates BCAA levels in blood, and hence BCAAs could be a novel biomarker of hypothalamic insulin action in patients with Alzheimer’s, which still needs to be confirmed in humans.
“This is the first study to suggest that Alzheimer’s disease pathology increases susceptibility to diabetes due to impaired insulin signaling in the hypothalamus,” said Christoph Buettner, MD, PhD, Associate Professor of Medicine, Endocrinology, Diabetes, Bone Disease and Neuroscience, Icahn School of Medicine at Mount Sinai, and lead author of the study. “Our research provides a rationale that therapies developed to improve insulin signaling in the brain may reduce the likelihood that a patient with Alzheimer’s disease develops diabetes.”
Alzheimer’s disease is a progressive and fatal brain disorder that gradually destroys a person’s memory and ability to learn, reason, make judgments, communicate, and carry out daily activities. AD is the most common form of dementia and sixth leading cause of death in the United States. Diabetes, the seventh leading cause of death nationally, is a metabolic disease that results in high blood sugar levels because the body does not produce enough insulin for proper function. Aging is known to be one of the top risk factors for both diseases, and several previous epidemiological studies have supported the hypothesis that diabetes increases a person’s risk for AD.
“Our findings represent a turning point in the understanding of the relationship between Alzheimer’s disease, type II diabetes and insulin resistance,” said Sam Gandy, MD, PhD, Professor of Neurology and Psychiatry; Associate Director, Mount Sinai Alzheimer’s Disease Research Center; and co-author of the study. “Compelling and unexpected results such as Dr. Buettner’s are driving a complete re-evaluation of how these diseases interact. Now that we have disease genes for dementia and diabetes, those genes are our ground zero, and the challenge is to work out all the steps and missteps between the gene and the patient and then to find interventions that cure those missteps.”
Henry Ruiz, PhD, a postdoctoral fellow in the Buettner lab, Icahn School of Medicine at Mount Sinai, also collaborated in the study.
The study was supported by the National Institute on Aging (NIA), one of the 27 Institutes and Centers of the National Institutes of Health (NIH), and the American Diabetes Association (ADA).
About the Mount Sinai Health SystemThe Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.
The System includes approximately 6,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is ranked as one of the nation’s top 10 hospitals in Geriatrics, Cardiology/Heart Surgery, and Gastroenterology, and is in the top 25 in five other specialties in the 2015-2016 “Best Hospitals” issue of U.S. News & World Report. Mount Sinai’s Kravis Children’s Hospital also is ranked in seven out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology, while Mount Sinai Beth Israel is ranked regionally.
For more information, visit http://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.# # #
RSS